<?xml version="1.0" encoding="UTF-8"?>
<ref id="B97-biomedicines-08-00109">
 <label>97.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ko</surname>
    <given-names>W.-C.</given-names>
   </name>
   <name>
    <surname>Rolain</surname>
    <given-names>J.-M.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>N.-Y.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>P.L.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>C.-T.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>P.-I.</given-names>
   </name>
   <name>
    <surname>Hsueh</surname>
    <given-names>P.-R.</given-names>
   </name>
  </person-group>
  <article-title>Arguments in favour of remdesivir for treating SARS-CoV-2 infections</article-title>
  <source>Int. J. Antimicrob. Agents</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105933</pub-id>
  <?supplied-pmid 32147516?>
  <pub-id pub-id-type="pmid">32147516</pub-id>
 </element-citation>
</ref>
